“We are pleased and honored to welcome Professor Nicod, Dr Herard and Mrs Glanard to NOVIGENIX’s Advisory Board,” said Dr Brian Hashemi, Executive Chairman of Novigenix. “The company will significantly benefit from their extensive and complementary experiences.”
, former Head of the in Lausanne, Switzerland, and currently pneumologist at the Clinic Cecil in Lausanne added :
“Novigenix is a promising enterprise with strong technology to unravel immune profiles in the blood for diagnostic and follow up of oncology and inflammatory diseases.”
, Executive Vice President, Global Sales, Services & Marketing at commented :
“I am extremely honored to join the Novigenix Advisory Board. During the recruitment process, I was truly impressed by all the Team’s immense knowledge and appetite to improve patient care. Bringing to the market LITOseek, an amazing data engine, will clearly revolutionize predictive medicine.”
, a urologist certified in cancer surgery and former deputy CEO and current Chairman of the Supervisory Board of the in Reims, France said:
“I’m delighted to join the Medical Advisory Board of Novigenix. The LITOseek® platform is a useful tool to predict patient immune response and help physicians improve personalized patient management. Precision Medicine is definitely the way to go!”
About Novigenix
Novigenix is a precision medicine biotech providing a new understanding of the human host response to cancer and its response to therapy. The Company was founded on the vision that Immuno-Transcriptomics will bring unprecedented advances in diagnosing and treating cancer patients, leading to significant improvement in healthcare. Novigenix’s unique Immuno-Transcriptomic platform enables an accelerated identification of disease specific mRNA signatures of immune cells, which combined with machine learning and predictive algorithms provide new insights into onset and progression of disease. For more information visit
About LITOseek
The Liquid Immuno-Transcriptomic Sequencing Platform of Novigenix, LITOseek, analyzes the gene expression modifications (mRNA signatures) induced by the host immune response to various triggers, such as onset of cancer. Disease specific algorithms are developed through application of Artificial Intelligence on patient mRNA signatures in combination with clinical and medical parameters. The LITOseek platform has been designed and optimized for development of precision oncology solutions based on the human Immuno-Transcriptome, with continuous improvement of predictive and adaptive algorithms.
Contacts
Novigenix
Valentin Matillon, President and Chief Business Officer
T: +41 21 552 07 30
E:
